Journal: Nucleic Acids Research

Article Title: Investigation of TRMT61B methyltransferase activity on mRNA and its effects on translation

doi: 10.1093/nar/gkag365

Figure Lengend Snippet: Overexpressed TRMT61B methylates thousands of sites across the transcriptome. ( A ) Schematic of TRMT61B overexpression (OE) in U-2 OS cells and m 1 A-IP. RNA was purified, polyA-selected, immunoprecipitated, and then prepared into libraries with a TruSeq Stranded mRNA Library Prep kit (Illumina). Both control and TRMT61B OE m 1 A-IP were carried out in duplicate. ( B ) Volcano plot showing DESeq2 results depicting fold changes in transcript abundance in m 1 A-IP samples compared to input samples under TRMT61B OE conditions. Top 30 hits by -log 10 (p adj ) are labeled, and mitochondrial genes are highlighted in red. ( C ) Volcano plot showing single-nucleotide sites called by bakR as having altered misincorporation levels in TRMT61B OE conditions versus control OE conditions, with “high-confidence” YMRA sites (bakR hits with additional filtering of P < .05, difference in log-odds of mutation rate >1, >1% mutation rate in both replicates, >5% average mutation rate in IP, and <5% average mutation rate in input samples) highlighted in red. Top 30 hits are labeled. ( D ) RNA types of all high-confidence single-nucleotide sites, regardless of methylated motif. ( E ) Regions of modification for all high-confidence sites, regardless of methylated motif. ( F ) Top motif discovered in high-confidence sites using STREME , covering 74.3% of all sites. ( G ) RNA type of high-confidence sites, filtered to only YMRA-motif sites. ( H ) Regions of modification for high-confidence sites, filtered to only YMRA-motif sites. ( I ) Metagene plot showing distribution of YMRA-containing high-confidence sites.

Article Snippet: U-2 OS cells (HTB-96) were obtained from the American Tissue Culture Collection and maintained in McCoy’s 5A Medium (Gibco, 16600082) with 10% fetal bovine serum and 1× penicillin–streptomycin at 37°C under a humidified atmosphere with 5% CO 2 .

Techniques: Over Expression, Purification, Immunoprecipitation, Control, Labeling, Mutagenesis, Methylation, Modification

Journal: Clinical Cancer Research

Article Title: A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function

doi: 10.1158/1078-0432.CCR-25-1444

Figure Lengend Snippet: APL-4098 is a potent inhibitor of GCN2. A, APL-4098 molecular structure. B, Crystal structure of APL-4098 bound to human GCN2. Backbone of the GCN2 catalytic site (blue ribbon) and binding of APL-4098, with the extensive interaction network in the ATP site shown with dashed red lines (hydrogen bonds) and yellow lines (hydrophobic contacts). C, Biochemical, ADME, and PK profile of APL-4098. *All data generated from a rat intravenous/oral study: 1 mg/kg i.v. and 3 mg/kg orally. 1 Data generated from the i.v. study and 2 data generated from the oral study. D, APL-4098 inhibition of GCN2 kinase activity, measured as the level of eIF2α phosphorylation, using LanthaScreen FRET-based assay. Plot shows mean ± SEM from three representative experiments conducted in duplicate. E, U2OS cells were treated with APL-4098 in the presence or absence of borrelidin as indicated for 4 hours. Cell lysates were analyzed for phosphorylation of eIF2α using HTRF assay. Plot shows mean ± SEM from four individual experiments conducted in duplicate. F, U2OS cells were grown in glutamine-depleted medium and treated with APL-4098 as indicated for 4 hours. Cell lysates were analyzed by Western blotting.

Article Snippet: The osteosarcoma cell line U2OS (HTB-96, RRID: CVCL_0042) was obtained from ATCC and cultured in DMEM high glucose (Gibco, #41965-039) with 10% FBS (Gibco, #10270-106), 1 mmol/L sodium pyruvate (Gibco, #11360-039), 1% nonessential amino acids (Gibco, #11140-035), and antibiotics (penicillin/streptomycin 100 U/mL and 100 μg/mL; Gibco, #15140-122).

Techniques: Binding Assay, Generated, Inhibition, Activity Assay, Phospho-proteomics, HTRF Assay, Western Blot

Journal: Clinical Cancer Research

Article Title: A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function

doi: 10.1158/1078-0432.CCR-25-1444

Figure Lengend Snippet: APL-4098 is a selective inhibitor of GCN2. A, Eurofins KINOMEScan selectivity panel assay Treespot results for APL-4098 tested at 1 μmol/L. B, Eurofins biochemical K d concentration–response assay. C, U2OS cells were treated with APL-4098 or positive control dabrafenib (bioRxiv 2024.08.14.607626) in the presence of BtdCPU for 4 hours. Cell lysates were analyzed for phosphorylation of eIF2α using HTRF assay. Plot shows mean ± SEM from three individual experiments conducted in duplicate. D, U2OS cells were treated with APL-4098 or positive control GSK2606414 in the presence of thapsigargin for 4 hours. Cell lysates were analyzed for phosphorylation of eIF2α using HTRF assay. Plot shows mean ± SEM from three individual experiments.

Article Snippet: The osteosarcoma cell line U2OS (HTB-96, RRID: CVCL_0042) was obtained from ATCC and cultured in DMEM high glucose (Gibco, #41965-039) with 10% FBS (Gibco, #10270-106), 1 mmol/L sodium pyruvate (Gibco, #11360-039), 1% nonessential amino acids (Gibco, #11140-035), and antibiotics (penicillin/streptomycin 100 U/mL and 100 μg/mL; Gibco, #15140-122).

Techniques: Concentration Assay, Positive Control, Phospho-proteomics, HTRF Assay

Journal: Chembiochem

Article Title: Monoclonal Antibodies Accessing the Cytosol of Living Cells and Binding to Polo‐Like Kinase 1 Interdomain Linker Affect Mitotic Behavior

doi: 10.1002/cbic.202500858

Figure Lengend Snippet: Anti‐PLK1 mAbs characterization. (A) Clones 35‐206, 3F8, and 13E8 were raised against full‐length PLK1, fragment 300–600, or fragment 300–400, respectively. KD: Kinase Domain; IDL: Interdomain Linker; PBD: Polo Box Domain. (B) Epitope mapping by Western blot. Lane 1: protein ladder; Lanes 2‐4: U2OS cells expressing 68 kDa PLK1, 14 kDa IDL (300–400), or 35 kDa IDL‐PBD (300–603), respectively.

Article Snippet: Human cervical carcinoma cells HeLa (ATCC Cat# CCL‐2, RRID:CVCL_0030), histone‐green fluorescent protein expressing HeLa cells H2BGFP‐HeLa (SCC117, Merck Millipore, RRID:CVCL_ZM02), human osteosarcoma cells U2OS (ATCC HTB‐96) U2OS (RRID:CVCL_0042) and human osteosarcoma cells expressing both luciferase (LUC) and green fluorescent protein (EGFP) (EGFPLuc‐U2OS, produced in our laboratory) were cultured adherently on plastic substrates (75 cm 2 Falcon tissue culture flasks) in high‐glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Perbio, Brebières, France), 2 mM L‐glutamine, 100 U/mL penicillin G, and 100 μg/mL streptomycin.

Techniques: Clone Assay, Western Blot, Expressing